Citrate modulates calciprotein particle formation and composition.

Area of Science:

• Biochemistry
• Materials Science
• Nephrology

Background:

• Chronic kidney disease (CKD) elevates cardiovascular disease (CVD) risk, partly via phosphate-driven vascular calcification.
• Fetuin-A normally stabilizes calcium-phosphate complexes into calciprotein particles (CPPs), but their maturation in CKD promotes calcification.
• Understanding CPP stabilization is crucial for developing therapies against CKD-associated vascular damage.

Purpose of the Study:

• To investigate citrate's ability to mitigate calciprotein particle (CPP)-induced vascular calcification in vitro.
• To characterize citrate's effects on CPP structure, maturation, and composition.

Main Methods:

• Vascular Smooth Muscle Cells (VSMC) were incubated with CPPs at varying citrate concentrations.
• Calcification was quantified using calcium assays.
• CPP characterization involved spectrophotometry, DLS, cryo-TEM, ED, Raman spectroscopy, EDX, and MS.

Main Results:

• High citrate concentrations reduced VSMC calcification by 88% and delayed CPP maturation.
• Citrate lowered CPP mean diameter and altered particle morphology, transitioning from primary to secondary CPPs.
• Citrate modified CPP composition, including mineral-to-protein ratios and protein enrichment, without changing Ca/P ratios.

Conclusions:

• Citrate remodels calciprotein particles (CPPs) into a less calcifying phenotype.
• Citrate demonstrates potential as a therapeutic strategy to prevent vascular calcification in chronic kidney disease (CKD).
• Further research into citrate's role in managing CKD-related cardiovascular complications is warranted.